BcellBiofactories

𝗟𝗶𝘃𝗶𝗻𝗴 𝗕𝗶𝗼𝗳𝗮𝗰𝘁𝗼𝗿𝗶𝗲𝘀: 𝗛𝗼𝘄 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗲𝗱 𝗕 𝗖𝗲𝗹𝗹𝘀 𝗮𝗻𝗱 𝗖𝘂𝘀𝘁𝗼𝗺 𝗚𝗣𝗧𝘀 𝗔𝗿𝗲 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘀𝗶𝗻𝗴 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆

𝑂𝑛 6 𝑀𝑎𝑦 2026, 𝐼𝑚𝑚𝑢𝑠𝑜𝑓𝑡 𝑎𝑛𝑛𝑜𝑢𝑛𝑐𝑒𝑑 𝑤ℎ𝑎𝑡 𝑚𝑎𝑦 𝑏𝑒 𝑟𝑒𝑚𝑒𝑚𝑏𝑒𝑟𝑒𝑑 𝑎𝑠 𝑎 𝑤𝑎𝑡𝑒𝑟𝑠ℎ𝑒𝑑 𝑚𝑜𝑚𝑒𝑛𝑡 𝑖𝑛 𝑡ℎ𝑒 ℎ𝑖𝑠𝑡𝑜𝑟𝑦 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑎𝑛𝑑 𝑔𝑒𝑛𝑒 𝑡ℎ𝑒𝑟𝑎𝑝𝑦: 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑟𝑒𝑠𝑢𝑙𝑡𝑠 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑤𝑜𝑟𝑙𝑑’𝑠 𝑓𝑖𝑟𝑠𝑡 𝑒𝑛𝑔𝑖𝑛𝑒𝑒𝑟𝑒𝑑 𝐵 𝑐𝑒𝑙𝑙 𝑡ℎ𝑒𝑟𝑎𝑝𝑦 𝑖𝑛 ℎ𝑢𝑚𝑎𝑛𝑠. 𝑃𝑟𝑒𝑠𝑒𝑛𝑡𝑒𝑑 𝑎𝑡 𝑡ℎ𝑒 𝐴𝑚𝑒𝑟𝑖𝑐𝑎𝑛 𝑆𝑜𝑐𝑖𝑒𝑡𝑦 𝑜𝑓 𝐶𝑒𝑙𝑙 𝑎𝑛𝑑 𝐺𝑒𝑛𝑒 𝑇ℎ𝑒𝑟𝑎𝑝𝑦 (𝐴𝑆𝐺𝐶𝑇) 29𝑡ℎ 𝐴𝑛𝑛𝑢𝑎𝑙 𝑀𝑒𝑒𝑡𝑖𝑛𝑔 𝑖𝑛 𝐵𝑜𝑠𝑡𝑜𝑛, 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎 𝑓𝑜𝑟 𝐼𝑆𝑃-001 𝑑𝑒𝑚𝑜𝑛𝑠𝑡𝑟𝑎𝑡𝑒𝑑 𝑓𝑎𝑣𝑜𝑢𝑟𝑎𝑏𝑙𝑒 𝑠𝑎𝑓𝑒𝑡𝑦, 𝑡𝑜𝑙𝑒𝑟𝑎𝑏𝑖𝑙𝑖𝑡𝑦, 𝑎𝑛𝑑 𝑒𝑛𝑐𝑜𝑢𝑟𝑎𝑔𝑖𝑛𝑔 𝑏𝑖𝑜𝑐ℎ𝑒𝑚𝑖𝑐𝑎𝑙 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑤𝑖𝑡ℎ 𝑀𝑢𝑐𝑜𝑝𝑜𝑙𝑦𝑠𝑎𝑐𝑐ℎ𝑎𝑟𝑖𝑑𝑜𝑠𝑖𝑠 𝑡𝑦𝑝𝑒 𝐼 (𝑀𝑃𝑆 𝐼) 𝑎 𝑟𝑎𝑟𝑒, 𝑙𝑒𝑡ℎ𝑎𝑙 𝑐ℎ𝑖𝑙𝑑ℎ𝑜𝑜𝑑 𝑔𝑒𝑛𝑒𝑡𝑖𝑐 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 𝑡ℎ𝑎𝑡 𝑎𝑓𝑓𝑒𝑐𝑡𝑠 𝑎𝑝𝑝𝑟𝑜𝑥𝑖𝑚𝑎𝑡𝑒𝑙𝑦 1 𝑖𝑛 100,000 𝑙𝑖𝑣𝑒 𝑏𝑖𝑟𝑡ℎ𝑠.

https://www.josephodongo.com/blog/engineered-b-cell-therapy-living-biofactories-rare-disease-custom-gpt-gptmarket-2026

Видео BcellBiofactories канала bioscreens